2'-O-(1,5-dicarbomethoxy-3-methoxypentan-3-yl)-N-3-toluoyluridine | 108782-96-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 2'-O-(1,5-dicarbomethoxy-3-methoxypentan-3-yl)-N-3-toluoyluridine
• CAS: 108782-96-3
• 化学式: C₂₇H₃₄N₂O₁₂
• 分子量: 578.573
• InChiKey: NLWHLHNZDHLIOQ-FQESCDNSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.11
• 重原子数：
  41.0
• 可旋转键数：
  12.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  181.82
• 氢给体数：
  2.0
• 氢受体数：
  14.0

反应信息

• 作为反应物：
  描述：

  2'-O-(1,5-dicarbomethoxy-3-methoxypentan-3-yl)-N-3-toluoyluridine 、 9-chloro-9-(4-octadecyloxyphenyl)xanthen 以 吡啶 为溶剂， 以71%的产率得到4-{(2R,3R,4R,5R)-4-Hydroxy-2-[3-(4-methyl-benzoyl)-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl]-5-[9-(4-octadecyloxy-phenyl)-9H-xanthen-9-yloxymethyl]-tetrahydro-furan-3-yloxy}-4-methoxy-heptanedioic acid dimethyl ester
  参考文献：
  名称：

  Site-specific modification of the pyrimidine residue during the deprotection of the fully-protected diuridylic acid

  摘要：

  DOI：

  10.1016/s0040-4020(01)88067-4
• 作为产物：
  描述：

  1,5-dicarbomethoxy-3-methoxy-2-pentene 、 N³-(4-methylbenzoyl)-3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)uridine 在 四丁基氟化铵 、 苯磺酸 作用下， 生成 2'-O-(1,5-dicarbomethoxy-3-methoxypentan-3-yl)-N-3-toluoyluridine
  参考文献：
  名称：

  Site-specific modification of the pyrimidine residue during the deprotection of the fully-protected diuridylic acid

  摘要：

  DOI：

  10.1016/s0040-4020(01)88067-4

文献信息

• New regiospecific synthesis of branched tetra-, nona- & deca-RNA modelling the lariat formed in RNA splicing reactions
  作者：C. Sund、A. Földesi、S. Yamakage、P. Agback、J. Chattopadhyaya

  DOI：10.1016/s0040-4020(01)86562-5

  日期：1991.8

  Convergent syntheses of branched tetraribonucleotide 39, nonaribonucleotide 40 and decaribonucleotide 41, modelling the lariat of pre-mRNA processing reaction, are reported. The first key step in the present strategy involves the condensation of the phosphodiester blocks 1, 5 or 15 with the 3',5'-dihydroxy-6-N-benzoyl-2'-O-pixyl(9-phenylxanthen-9-yl)adenosine 29 to give 30a (65%), 31a (63%) or 32a (70%). Chemospecific phosphorylation at 3'-OH of these intermediates afforded the intermediates 30b (92%), 31b (83%) or 32b (80%) which were treated with mild acid to achieve a regiospecific removal of the 2'-O-pixyl group to give compounds 30c (74%), 31c (86%) or 32c (85%). The second key step involved the introduction of biscyanoethylphosphotriester moiety to the 2'-OH of the branch-point adenosine in 30c, 31c or 32c in one single step using (biscyanoethoxy)-(diisopropylamino)phosphine to give the crucial branch-point building blocks 30d (46%), 31d (64%) or 32d (62%) with two dissimilar vicinal phosphates at 2'- and 3'- of the branch-point. These blocks were then converted to the fully protected intermediates 33a (59%) [30d+28 --> 33a], 34a (69%) [31d+19 --> 34a] and 35a (56%) [32d+19 --> 35a], and were subsequently treated with a bulky tertiary amine to give the branch-point 2'-cyanoethylphosphodiester blocks 33b (64%), 34b (67%) and 35b (68%). These were then condensed in the usual way with the appropriate 5'-hydroxy block (27 or 25) to give the fully protected branched oligomers 36 (69%) [33b+27 --> 36], 37 (67%) [34b+25 --> 37] and 38 (63%) [35b+25 --> 38]. These oligomers were then deprotected in the usual manner to give the final branched oligoribonucleotides 39, 40 and 41 in 62%, 21% and 21% yields respectively. Detailed 500 MHz H-1-NMR and 202.4 MHz P-31-NMR studies on 39, 40 and 41 have unequivocally established their purities. Detailed spectroscopic studies such as COSY, HOHAHA & NOESY have also clearly established the structural integrity of the synthetic target compounds.